Cardiology Updates
Open in Telegram
All the atest articles, research and news from worlds leading Cardiology Journals. Discussion group https://t.me/Professional_Medical_Discussion
Show more📈 Analytical overview of Telegram channel Cardiology Updates
Channel Cardiology Updates (@cardiology_updates) in the English language segment is an active participant. Currently, the community unites 19 522 subscribers, ranking 1 179 in the Medicine category and 1 986 in the USA region.
📊 Audience metrics and dynamics
Since its creation on невідомо, the project has demonstrated rapid growth, gathering an audience of 19 522 subscribers.
According to the latest data from 07 September, 2026, the channel demonstrates stable activity. Although there has been a change in the number of participants by 562 over the last 30 days and by 20 over the last 24 hours, overall reach remains high.
- Verification status: Not verified
- Engagement rate (ER): The average audience engagement rate is 12.86%. Within the first 24 hours after publication, content typically collects 3.21% reactions from the total number of subscribers.
- Post reach: On average, each post receives 2 510 views. Within the first day, a publication typically gains 626 views.
- Reactions and interaction: The audience actively supports content: the average number of reactions per post is 1.
- Thematic interests: Content is focused on key topics such as association, disease, resuscitation, patient, cardiology.
📝 Description and content policy
The author describes the resource as a platform for expressing subjective opinions:
“All the atest articles, research and news from worlds leading Cardiology Journals.
Discussion group
https://t.me/Professional_Medical_Discussion”
Thanks to the high frequency of updates (latest data received on 08 September, 2026), the channel maintains relevance and a high level of publication reach. Analytics show that the audience actively interacts with content, making it an important point of influence in the Medicine category.
19 522
Subscribers
+2024 hours
+947 days
+56230 days
Data loading in progress...
Similar Channels
Tags Cloud
Incoming and Outgoing Mentions
---
---
---
---
---
---
Attracting Subscribers
September '26
September '26
+98
in 0 channels
August '26
+612
in 0 channels
Get PRO
July '26
+686
in 0 channels
Get PRO
June '26
+586
in 0 channels
Get PRO
May '26
+723
in 0 channels
Get PRO
April '26
+559
in 0 channels
Get PRO
March '26
+201
in 0 channels
Get PRO
February '26
+308
in 0 channels
Get PRO
January '26
+345
in 0 channels
Get PRO
December '25
+324
in 0 channels
Get PRO
November '25
+361
in 2 channels
Get PRO
October '25
+384
in 0 channels
Get PRO
September '25
+574
in 0 channels
Get PRO
August '25
+663
in 0 channels
Get PRO
July '25
+283
in 0 channels
Get PRO
June '25
+18
in 0 channels
Get PRO
May '25
+170
in 0 channels
Get PRO
April '25
+105
in 0 channels
Get PRO
March '25
+73
in 1 channels
Get PRO
February '25
+176
in 3 channels
Get PRO
January '25
+14
in 3 channels
Get PRO
December '24
+327
in 0 channels
Get PRO
November '24
+1 438
in 0 channels
Get PRO
October '24
+1 550
in 0 channels
Get PRO
September '24
+1 665
in 29 channels
Get PRO
August '24
+1 045
in 0 channels
Get PRO
July '24
+711
in 0 channels
Get PRO
June '24
+644
in 0 channels
Get PRO
May '24
+710
in 0 channels
Get PRO
April '24
+658
in 1 channels
Get PRO
March '24
+765
in 0 channels
Get PRO
February '24
+841
in 0 channels
Get PRO
January '24
+1 116
in 0 channels
Get PRO
December '23
+912
in 0 channels
Get PRO
November '23
+34
in 0 channels
Get PRO
October '23
+44
in 1 channels
Get PRO
September '23
+32
in 0 channels
Get PRO
August '23
+48
in 0 channels
Get PRO
July '23
+46
in 0 channels
Get PRO
June '23
+41
in 0 channels
Get PRO
May '23
+42
in 0 channels
Get PRO
April '23
+45
in 0 channels
Get PRO
March '23
+57
in 0 channels
Get PRO
February '23
+41
in 0 channels
Get PRO
January '23
+45
in 0 channels
Get PRO
December '22
+46
in 0 channels
Get PRO
November '22
+113
in 0 channels
Get PRO
October '22
+40
in 0 channels
Get PRO
September '22
+101
in 0 channels
Get PRO
August '22
+62
in 0 channels
Get PRO
July '22
+53
in 0 channels
Get PRO
June '22
+251
in 0 channels
Get PRO
May '22
+39
in 0 channels
Get PRO
April '22
+34
in 0 channels
Get PRO
March '22
+21
in 0 channels
Get PRO
February '22
+10
in 0 channels
Get PRO
January '22
+27
in 0 channels
Get PRO
December '21
+28
in 0 channels
Get PRO
November '21
+21
in 0 channels
Get PRO
October '21
+32
in 0 channels
Get PRO
September '21
+37
in 0 channels
Get PRO
August '21
+30
in 0 channels
Get PRO
July '21
+41
in 0 channels
Get PRO
June '21
+77
in 0 channels
Get PRO
May '21
+90
in 0 channels
Get PRO
April '21
+293
in 0 channels
Get PRO
March '21
+156
in 0 channels
Get PRO
February '21
+23
in 0 channels
Get PRO
January '21
+30
in 0 channels
Get PRO
December '20
+536
in 0 channels
| Date | Subscriber Growth | Mentions | Channels | |
| 08 September | +4 | |||
| 07 September | +20 | |||
| 06 September | +9 | |||
| 05 September | +28 | |||
| 04 September | +8 | |||
| 03 September | +6 | |||
| 02 September | +13 | |||
| 01 September | +10 |
Channel Posts
Fishing for answers: omega-3 fatty acids and cardiovascular health
https://www.nature.com/articles/s41569-026-01347-y
Nature Reviews Cardiology, Published online: 03 September 2026; doi:10.1038/s41569-026-01347-y (https://www.nature.com/articles/s41569-026-01347-y)Ludmila Caceva discusses the 1970s studies that revealed that the plasma lipid prolife of the Inuit population of Greenland, who had a low incidence of cardiovascular disease, was characterized by low levels of cholesterol, lipoproteins and triglycerides and high levels of omega-3 fatty acids and how these findings shaped dietary guidelines worldwide.
| 2 | Langendorff-free dissociation of adult mouse hearts
https://www.nature.com/articles/s41569-026-01346-z
Nature Reviews Cardiology, Published online: 02 September 2026; doi:10.1038/s41569-026-01346-z (https://www.nature.com/articles/s41569-026-01346-z)In this Tools of the Trade, Ackers-Johnson and Pavlovic describe a Langendorff-free approach to isolate cardiomyocytes without the technical hurdles associated with the conventional Langendorff perfusion procedure. | 1 443 |
| 3 | Identifying the coronary metabolic dilator
https://www.nature.com/articles/s41569-026-01345-0
Nature Reviews Cardiology, Published online: 01 September 2026; doi:10.1038/s41569-026-01345-0 (https://www.nature.com/articles/s41569-026-01345-0)Adam Goodwill discusses Eric Feigl’s seminal description of coronary physiology and how his paper shaped research into the mechanisms by which coronary blood flow is matched to myocardial metabolism. | 1 571 |
| 4 |  https://www.instagram.com/updates_in_medicine?igsi=eWJ2N3p2MmxvNXJ0&utm_source=qr | 1 270 |
| 5 | Dyslipidaemia and hepatic steatosis: mechanisms and implications for lipid-lowering therapy
https://www.nature.com/articles/s41569-026-01336-1
Nature Reviews Cardiology, Published online: 27 August 2026; doi:10.1038/s41569-026-01336-1 (https://www.nature.com/articles/s41569-026-01336-1)Dyslipidaemia and hepatic steatosis are interconnected disorders that contribute to the burden of cardiovascular disease. Understanding the interactions between lipoprotein metabolism, changes in circulating lipids and hepatic lipid accumulation is, therefore, essential for improving risk stratification and therapeutic strategies. In this Review, Averna and colleagues discuss mechanistic links between dyslipidaemia and hepatic steatosis, the clinical relevance of the balance between circulating lipids and hepatic lipid content and the effects of lipid-lowering therapies on hepatic steatosis. | 2 584 |
| 6 | Reply to ‘Bedside epicardial adipose tissue assessment in the era of advanced adipose phenotyping’
https://www.nature.com/articles/s41569-026-01343-2
Nature Reviews Cardiology, Published online: 27 August 2026; doi:10.1038/s41569-026-01343-2 (https://www.nature.com/articles/s41569-026-01343-2)Reply to ‘Bedside epicardial adipose tissue assessment in the era of advanced adipose phenotyping’ | 2 132 |
| 7 | Bedside epicardial adipose tissue assessment in the era of advanced adipose phenotyping
https://www.nature.com/articles/s41569-026-01344-1
Nature Reviews Cardiology, Published online: 27 August 2026; doi:10.1038/s41569-026-01344-1 (https://www.nature.com/articles/s41569-026-01344-1)Bedside epicardial adipose tissue assessment in the era of advanced adipose phenotyping | 1 965 |
| 8 | Nicotine-containing products and the cardiovascular system: mechanisms and global health implications
https://www.nature.com/articles/s41569-026-01331-6
Nature Reviews Cardiology, Published online: 20 August 2026; doi:10.1038/s41569-026-01331-6 (https://www.nature.com/articles/s41569-026-01331-6)In this Review, Münzel and colleagues discuss the available mechanistic, biomarker, preclinical and clinical data on the cardiovascular effects of nicotine-containing products, define a hierarchy of cardiovascular harm across nicotine-containing products, summarize global policies on nicotine products, and highlight clinical implications and knowledge gaps. | 3 081 |
| 9 | Cardiovascular research in China: pathways, incentives and editorial implications
https://www.nature.com/articles/s41569-026-01341-4
Nature Reviews Cardiology, Published online: 19 August 2026; doi:10.1038/s41569-026-01341-4 (https://www.nature.com/articles/s41569-026-01341-4)The cardiovascular research landscape in China is shaped by a tiered, hospital-centred system, expanding funding opportunities and strong clinical resources. This Comment examines how institutional structures, research pathways and publication expectations influence scientific output and highlights how greater methodological rigour, international collaboration and more effective communication of scientific relevance to global audiences could improve the global visibility and impact of cardiovascular research from China. | 2 788 |
| 10 | Cardiac fibroblast diversity in HFpEF: states, niches, interorgan drivers and targets
https://www.nature.com/articles/s41569-026-01335-2
Nature Reviews Cardiology, Published online: 18 August 2026; doi:10.1038/s41569-026-01335-2 (https://www.nature.com/articles/s41569-026-01335-2)Myocardial fibrosis is a key structural and prognostically adverse feature of heart failure with preserved ejection fraction (HFpEF). In this Review, Kaye and colleagues delineate HFpEF-specific fibroblast alterations, integrate cross-organ signalling networks that condition the cardiac stroma, and evaluate opportunities for fibroblast-directed therapies as next-generation antifibrotic strategies. | 2 658 |
| 11 | Atherosclerotic plaque-derived microparticles as exporters of thrombotic risk
https://www.nature.com/articles/s41569-026-01340-5
Nature Reviews Cardiology, Published online: 18 August 2026; doi:10.1038/s41569-026-01340-5 (https://www.nature.com/articles/s41569-026-01340-5)Tipack Shanmugam discusses a study showing that microparticles released from atherosclerotic plaque can increase thrombotic risk and proposes that these extracellular vesicles might be therapeutically altered to prevent plaque rupture. | 2 422 |
| 12 | Uncovering the role of chromatin organization and dynamics in heart disease
https://www.nature.com/articles/s41569-026-01338-z
Nature Reviews Cardiology, Published online: 11 August 2026; doi:10.1038/s41569-026-01338-z (https://www.nature.com/articles/s41569-026-01338-z)Two studies published in Science explore how 3D chromatin organization and structure can influence cardiac development and promote heart failure. | 3 234 |
| 13 | The biomechanical environment of coronary atherosclerotic plaque rupture
https://www.nature.com/articles/s41569-026-01337-0
Nature Reviews Cardiology, Published online: 11 August 2026; doi:10.1038/s41569-026-01337-0 (https://www.nature.com/articles/s41569-026-01337-0)Tsiartas and Bennett discuss the discovery that atheroclerotic plaque vulnerability to rupture arises from the interaction between plaque composition and vessel biomechanics. | 3 046 |
| 14 | Haemolytic injury and cardiovascular disease
https://www.nature.com/articles/s41569-026-01329-0
Nature Reviews Cardiology, Published online: 06 August 2026; doi:10.1038/s41569-026-01329-0 (https://www.nature.com/articles/s41569-026-01329-0)Haemolysis, and the subsequent liberation of haemoglobin into the plasma, can induce haemodynamic dysregulation and cardiovascular injury. In this Review, Hieromnimon and colleagues discuss the mechanisms by which plasma free haemoglobin and its degradation products exert their deleterious effects, the pathophysiological responses to these derangements and the potential preventative and therapeutic approaches to haemolytic injury. | 3 908 |
| 15 | Social determinants of cardiovascular health: lessons from Whitehall
https://www.nature.com/articles/s41569-026-01333-4
Nature Reviews Cardiology, Published online: 03 August 2026; doi:10.1038/s41569-026-01333-4 (https://www.nature.com/articles/s41569-026-01333-4)Benjamin Dowsing describes the Whitehall studies, which established the inverse relationship between socioeconomic status and the risk of death from coronary heart disease, leading to the concept of social determinants of health. | 3 621 |
| 16 | Post-mitotic cardiomyocyte senescence redefines cardiac ageing
https://www.nature.com/articles/s41569-026-01332-5
Nature Reviews Cardiology, Published online: 03 August 2026; doi:10.1038/s41569-026-01332-5 (https://www.nature.com/articles/s41569-026-01332-5)Ilias Simon and Yohan Santin discuss the study that demonstrated that post-mitotic cardiomyocytes can acquire a senescent phenotype with age. | 3 172 |
| 17 | Mitochondrial uncoupling therapy reduces established atherosclerosis in mice
https://www.nature.com/articles/s41569-026-01330-7
Nature Reviews Cardiology, Published online: 28 July 2026; doi:10.1038/s41569-026-01330-7 (https://www.nature.com/articles/s41569-026-01330-7)Targeting systemic metabolism through mild mitochondrial uncoupling with a controlled-release mitochondrial protonophore can reduce atherosclerosis in a mouse model of cardiometabolic syndrome, even when administered at late stages of disease progression. | 3 595 |
| 18 | Cardioprotective properties of empagliflozin and other SGLT2 inhibitors
https://www.nature.com/articles/s41569-026-01325-4
Nature Reviews Cardiology, Published online: 27 July 2026; doi:10.1038/s41569-026-01325-4 (https://www.nature.com/articles/s41569-026-01325-4)In this Review, Zelniker and Braunwald summarize the cardioprotective effects of empagliflozin and other sodium–glucose cotransporter 2 inhibitors and discuss the underlying mechanisms of these effects, including haemodynamic modulation, improved mitochondrial bioenergetics and activation of cytoprotective pathways that inhibit oxidative stress, inflammation and fibrosis. | 3 416 |
| 19 | The cardiac 4D nucleome: nuclear and chromatin dynamics across development, disease and ageing
https://www.nature.com/articles/s41569-026-01322-7
Nature Reviews Cardiology, Published online: 23 July 2026; doi:10.1038/s41569-026-01322-7 (https://www.nature.com/articles/s41569-026-01322-7)In this Review, Wang and Dobreva discuss nuclear and chromatin organization and remodelling during cardiac development, disease and ageing, highlight emerging methods to investigate nuclear architecture, describe how mechanical and metabolic signals shape the cardiac 4D nucleome, and examine the therapeutic and translational implications for cardiovascular health and disease. | 3 545 |
| 20 | The renaissance of cardiac glycosides in heart failure: why, for whom and when
https://www.nature.com/articles/s41569-026-01323-6
Nature Reviews Cardiology, Published online: 17 July 2026; doi:10.1038/s41569-026-01323-6 (https://www.nature.com/articles/s41569-026-01323-6)Cardiac glycosides were the cornerstone of heart failure treatment for decades, but their use progressively declined after the introduction of modern prognostic medications. Two clinical trials now report that cardiac glycosides can reduce the risk of worsening heart failure events in patients with heart failure with reduced ejection fraction. These results do not mandate a paradigm shift but support a specific role for cardiac glycosides in selected patients. | 4 077 |
